Physician profile
David Greeson
NPI 1417951450
$3,973.56
in general payments reported to CMS, 2019-2025
35 companies · $950 in 2025
The $950 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2021: $78.63 · 2022: $587 · 2023: $851 · 2024: $1,325 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,033 · Education: $93.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,033.41 |
| Education | $93.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $881.71 | 2019-2025 | |
| Janssen Biotech, INC. | $619.19 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $324.77 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $275.33 | 2019-2025 | Dupixent |
| Amgen INC. | $273.11 | 2022-2025 | Otezla, Otezla |
| Ucb, INC. | $157.82 | 2023-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $125.05 | 2019-2023 | |
| Incyte Corporation | $124.52 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $97.75 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $96.66 | 2024-2025 | Acthar |
| Convatec INC. | $89.58 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.17 | 2022-2024 | Spevigo |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Genzyme Corporation | $79.34 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $71.33 | 2021-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $52.40 | 2022-2024 | Aklief |
| Organon LLC | $49.24 | 2023-2025 | Hadlima, Vtama |
| E.R. Squibb & Sons, L.L.C. | $47.44 | 2022-2023 | Sotyktu |
| Leo Pharma INC. | $46.01 | 2023-2024 | Adbry |
| Dermavant Sciences, INC. | $45.38 | 2024 | Vtama |
| Botanix Sb INC | $41.34 | 2025 | Sofdra |
| Genentech USA, INC. | $40.36 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.56 | 2019-2024 | Arazlo, Jublia |
| Journey Medical Corporation | $29.91 | 2022-2025 | |
| Strata Skin Sciences, INC. | $29.21 | 2024 | Xtrac |
| Organogenesis INC. | $25.70 | 2025 | Affinity |
| Novartis Pharmaceuticals Corporation | $22.91 | 2024 | |
| Biofrontera INC. | $21.92 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Verrica Pharmaceuticals INC. | $18.52 | 2024 | Ycanth |
| Mimedx Group, INC. | $18.19 | 2025 | |
| Arcutis Biotherapeutics, INC. | $16.92 | 2025 | Zoryve |
| Alpha Orthopedic Systems | $15.56 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Solta Medical, A Division of Bausch Health US, LLC | $12.02 | 2022 | |
| Kerecis Limited | $10.48 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Greeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.